Metastatic Uveal Melanoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Metastatic Uveal Melanoma – Drugs In Development, 2024 report and make more profitable business decisions.
Metastatic uveal melanoma is a rare and aggressive form of cancer that originates in the pigmented cells of the eye, specifically in the uvea, which includes the iris, ciliary body, and choroid. While the primary tumor in the eye may be treatable, metastatic spread of uveal melanoma to other parts of the body, such as the liver, lungs, bones, or other organs, is associated with a poor prognosis.
Uveal melanoma is the most common primary intraocular malignancy in adults. Initially, it may cause few symptoms or be asymptomatic. Common signs include changes in vision, such as blurred vision, visual disturbances, or seeing flashes of light. In some cases, a dark spot on the iris or sudden onset of floaters may be observed. Despite successful treatment of the primary tumor, up to 50% of patients with uveal melanoma will eventually develop metastatic disease, often involving the liver as the most common site of spread. Metastases to other organs, including the lungs, bones, and skin, can also occur. Risk factors for metastatic uveal melanoma include larger tumor size, older age, certain genetic mutations, and specific characteristics of the primary tumor, such as the presence of specific genetic abnormalities. Diagnosis involves a comprehensive eye examination by an ophthalmologist, which may include specialized tests such as ultrasound, fluorescein angiography, or optical coherence tomography. Confirmation of uveal melanoma may require a biopsy of the eye or fine-needle aspiration biopsy.
The Metastatic Uveal Melanoma drugs in development market research report provide comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Metastatic Uveal Melanoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 44 molecules, with 41 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Metastatic Uveal Melanoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Metastatic Uveal Melanoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Metastatic Uveal Melanoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acrotech Biopharma LLCAdagene Suzhou Ltd
AstraZeneca Plc
BioInvent International AB
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Galectin Therapeutics Inc
Ideaya Biosciences Inc
Immunocore Holdings Plc
Inxmed (Nanjing) Co Ltd
Linnaeus Therapeutics Inc
Lyvgen Biopharma Ltd
MediciNova Inc
Merck & Co Inc
Mirati Therapeutics Inc
Modulation Therapeutics Inc
Nino Jesus University Children's Hospital
Novartis AG
OncoSpherix Inc
Pfizer Inc
Provectus Biopharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Replimune Ltd
Roca Therapeutics SAS
Seagen Inc
Takeda Pharmaceutical Co Ltd
TriSalus Life Sciences Inc
Turnstone Biologics Inc
University Hospital Erlangen
University of Pittsburgh
Vanquish Oncology Inc
Verastem Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Metastatic Uveal Melanoma reports